- Home
- ICU vs LGVN Comparison
ICU vs LGVN Comparison
Compare ICU & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICU | LGVN |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ICU | LGVN |
|---|---|---|
| Price | $0.31 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | ★ 2.3M | 408.1K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $881,000.00 | ★ $1,437,000.00 |
| Revenue This Year | $691.85 | N/A |
| Revenue Next Year | $64.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1195.59 | N/A |
| 52 Week Low | $0.29 | $0.58 |
| 52 Week High | $3.07 | $2.24 |
Technical Indicators
Market Signals| Indicator | ICU | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 34.42 |
| Support Level | $0.32 | $0.58 |
| Resistance Level | $0.36 | $0.65 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 14.16 | 0.00 |
Price Performance
Historical ComparisonAbout ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.